Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term outperformance, it remains bullish based primarily on upside from Biktarvy led near-term HIV growth and lenacapavir driven long-term growth. It sees “upside growth” in Gilead’s combined HIV franchise and believes lenacapavir “could boost” its next phase of growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead reports results from pivotal Phase 3 PURPOSE 2 trial
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Gilead price target raised to $95 from $85 at TD Cowen
- Gilead price target raised to $97 from $83 at Truist
- Gilead price target raised to $103 from $95 at Raymond James
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
